Skip to main content

Advertisement

Log in

DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous?

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The diagnostic accuracy of dehydroepiandrosterone sulfate (DHEAS) to predict subclinical Cushing’s syndrome (sCS) has been a matter of debate. The primary objective of this study was to assess the diagnostic power of DHEAS in predicting sCS. This retrospective study was conducted in a tertiary referral center and based on subjects referred between 2004 and 2014. Data of 249 subjects with adrenal incidentalomas were evaluated. We also reviewed 604 DHEAS measurements from adults, which were performed during the same period in our laboratory (LB group). Adrenocortical function, tumor size, and clinical characteristics were assessed. We diagnosed sCS in 15.2 % of the participants in the presence of ≥2 of the following; 1 mg dexamethasone suppression test >3.0 μg/dl, urinary free cortisol >70 μg/24 h, and corticotrophin (ACTH) <10 pg/ml. DHEAS levels were significantly reduced in patients with sCS (n = 38) compared to sCS (−) (n = 141) and LB groups (n = 604) (27.95, 65.90, and 66.80 µg/dl, respectively, p < 0.001) while age was comparable. The ROC curve analysis showed that the cut-off of the DHEAS with the best diagnostic accuracy for detecting sCS was 40.0 μg/dl (SN, 68 %; SP, 75; PPV, 43 %; NPV, 90 %, AUC: 0.788, p < 0.001). Logistic regression assessed the impact of age, BMI, low DHEAS (<40 μg/dl), bilateral tumors, and tumor size on the likelihood of having sCS. The strongest predictor was low DHEAS, recording an OR of 9.41. DHEAS levels are inversely associated with the extent of cortisol excess. In subjects with intermediate laboratory findings, detection of low DHEAS could be advantageous for distinguishing sCS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. M. Terzolo, G. Osella, A. Ali, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. (Oxf). 48, 89–97 (1998)

    Article  CAS  PubMed  Google Scholar 

  2. D.A. Vassiliadi, S. Tsagarakis, Subclinical hypercortisolism: debatable or visible on the lightbox? Endocrine 42, 7–8 (2012)

    Article  CAS  PubMed  Google Scholar 

  3. A. Colao, M. Boscaro, D. Ferone, F.F. Casanueva, Managing Cushing’s disease: the state of the art. Endocrine (2014). doi:10.1007/s12020-013-0129-2

    Google Scholar 

  4. V. Morelli, C. Eller-Vainicher, A.S. Salcuni, Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J. Bone Miner. Res. 26, 1816–1821 (2011)

    Article  PubMed  Google Scholar 

  5. W.F. Young Jr, Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol. Metab. Clin. North Am. 29, 159–185 (2000)

    Article  PubMed  Google Scholar 

  6. I. Chiodini, V. Morelli, A.S. Salcuni, Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 95, 2736–2745 (2010)

    Article  CAS  PubMed  Google Scholar 

  7. G. Osella, M. Terzolo, G. Borretta, Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J. Clin. Endocrinol. Metab. 79, 1532–1539 (1994)

    Article  CAS  PubMed  Google Scholar 

  8. R. Rossi, L. Tauchmanova, A. Luciano, Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85, 1440–1448 (2000)

    CAS  PubMed  Google Scholar 

  9. M. Terzolo, S. Bovio, A. Pia, Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur. J. Endocrinol. 153, 307–315 (2005)

    Article  CAS  PubMed  Google Scholar 

  10. S. Fischli, S. Jenni, S. Allemann, Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 93, 539–542 (2008)

    Article  CAS  PubMed  Google Scholar 

  11. Y. Akehi, H. Kawate, K. Murase, Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adrenal incidentaloma. Endocr. J. 60, 903–912 (2013)

    Article  CAS  PubMed  Google Scholar 

  12. T. Katabami, R. Obi, N. Shirai, S. Naito, N. Saito, Discrepancies in results of low-and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing’s syndrome. Endocr. J. 52, 463–469 (2005)

    Article  PubMed  Google Scholar 

  13. M.A. Zeiger, G.B. Thompson, Q.Y. Duh, The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(Suppl 1), 1–20 (2009)

    Article  PubMed  Google Scholar 

  14. Z. Bencsik, I. Szabolcs, Z. Kovacs, Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J. Clin. Endocrinol. Metab. 81, 1726–1729 (1996)

    CAS  PubMed  Google Scholar 

  15. A. Tanabe, M. Naruse, T. Nishikawa, Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Horm. Metab. Res. 33, 444–450 (2001)

    Article  CAS  PubMed  Google Scholar 

  16. I. Chiodini, Clinical review: diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 96, 1223–1236 (2011)

    Article  CAS  PubMed  Google Scholar 

  17. V. Morelli, B. Masserini, A.S. Salcuni, Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin. Endocrinol. (Oxf). 73, 161–166 (2010)

    CAS  PubMed  Google Scholar 

  18. Diagnosis and classification of diabetes mellitus, Diabetes Care 27(Suppl 1), S5–S10 (2004)

    Google Scholar 

  19. J. Perk, G. De Backer, H. Gohlke, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33, 1635–1701 (2012)

    Article  CAS  PubMed  Google Scholar 

  20. H. Morio, T. Terano, K. Yamamoto, Serum levels of dehydroepiandrosterone sulfate in patients with asymptomatic cortisol producing adrenal adenoma: comparison with adrenal Cushing’s syndrome and non-functional adrenal tumor. Endocr. J. 43, 387–396 (1996)

    Article  CAS  PubMed  Google Scholar 

  21. S. Tsagarakis, C. Roboti, P. Kokkoris, V. Vasiliou, C. Alevizaki, N. Thalassinos, Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin. Endocrinol. (Oxf). 49, 165–171 (1998)

    Article  CAS  PubMed  Google Scholar 

  22. R. Giordano, E. Marinazzo, R. Berardelli, Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur. J. Endocrinol. 162, 779–785 (2010)

    Article  CAS  PubMed  Google Scholar 

  23. H. Olsen, E. Nordenstrom, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42, 164–173 (2012)

    Article  CAS  PubMed  Google Scholar 

  24. D.A. Vassiliadi, G. Ntali, E. Vicha, S. Tsagarakis, High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin. Endocrinol. (Oxf). 74, 438–444 (2010)

    Article  Google Scholar 

  25. C. Eller-Vainicher, V. Morelli, A.S. Salcuni, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur. J. Endocrinol. 163, 925–935 (2010)

    Article  CAS  PubMed  Google Scholar 

  26. N. Valli, B. Catargi, N. Ronci, Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur. J. Endocrinol. 144, 401–408 (2001)

    Article  CAS  PubMed  Google Scholar 

  27. H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 44, 346–349 (2013)

    Article  CAS  PubMed  Google Scholar 

  28. T.L. Mazzuco, I. Bourdeau, A. Lacroix, Adrenal incidentalomas and subclinical Cushing’s syndrome: diagnosis and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 16, 203–210 (2009)

    CAS  PubMed  Google Scholar 

  29. B. Masserini, V. Morelli, S. Bergamaschi, The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur. J. Endocrinol. 160, 87–92 (2009)

    Article  CAS  PubMed  Google Scholar 

  30. M.L. Nunes, S. Vattaut, J.B. Corcuff, Late-night salivary cortisol for diagnosis of overt and subclinical Cushing’s syndrome in hospitalized and ambulatory patients. J. Clin. Endocrinol. Metab. 94, 456–462 (2009)

    Article  CAS  PubMed  Google Scholar 

  31. S. Kidambi, H. Raff, J.W. Findling, Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur. J. Endocrinol. 157, 725–731 (2007)

    Article  CAS  PubMed  Google Scholar 

  32. M. Sereg, J. Toke, A. Patocs, Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. Steroids 76, 38–42 (2010)

    Article  Google Scholar 

  33. C. Invitti, F. Pecori Giraldi, M. de Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J. Clin. Endocrinol. Metab. 84, 440–448 (1999)

    CAS  PubMed  Google Scholar 

  34. I. Chiodini, V. Morelli, B. Masserini, Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 94, 3207–3214 (2009)

    Article  CAS  PubMed  Google Scholar 

  35. M.M. Grumbach, B.M. Biller, G.D. Braunstein, Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med. 138, 424–429 (2003)

    Article  PubMed  Google Scholar 

  36. L.K. Nieman, B.M. Biller, J.W. Findling, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. M. Reincke, J. Nieke, G.P. Krestin, W. Saeger, B. Allolio, W. Winkelmann, Preclinical Cushing’s syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing’s syndrome. J. Clin. Endocrinol. Metab. 75, 826–832 (1992)

    CAS  PubMed  Google Scholar 

  38. A. Tabarin, S. Bardet, J. Bertherat, Exploration and management of adrenal incidentalomas French Society of Endocrinology Consensus. Ann. Endocrinol. (Paris) 69, 487–500 (2008)

    Article  CAS  Google Scholar 

  39. M. Terzolo, A. Stigliano, I. Chiodini, AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164, 851–870 (2011)

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The authors have nothing to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Serkan Yener.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yener, S., Yilmaz, H., Demir, T. et al. DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous?. Endocrine 48, 669–676 (2015). https://doi.org/10.1007/s12020-014-0387-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0387-7

Keywords

Navigation